The RSA Group
@theRSAgroup
Followers
569
Following
1K
Media
558
Statuses
2K
We #connect elite #lifescience #talent with extraordinary organisations pioneering #medical advances.
EMEA | North America | APAC
Joined September 2008
The BIA’s 2035 vision for UK life sciences emphasises the need to boost late-stage capital and scale up companies to remain globally competitive. Addressing funding gaps and attracting talent will drive growth and innovation to improve global health.
0
0
0
Biosimilars are expanding access to affordable biologic therapies for chronic conditions, with the WHO leading efforts to strengthen regulatory frameworks and global partnerships to improve their availability and quality. Learn more here:
who.int
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, auto-immune diseases, and diabetes. These therapies can offer significant benefits...
0
1
0
Chronos-PD, a groundbreaking initiative led by global healthcare leader Grifols, is working to identify early biomarkers of Parkinson’s disease using plasma samples, thus potentially enabling earlier interventions and averting damage. Learn more here: https://t.co/xiV0ZRfj7s .
drugtargetreview.com
Grifols' Chronos-PD initiative leverages its plasma repository to identify biomarkers for Parkinson’s disease.
0
0
0
The UK biotech sector raised £3.5B in 2024, a 94% increase from 2023, despite economic and regulatory challenges. The sector stays resilient, driving innovation with promising progress ahead.
labiotech.eu
The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.
0
0
0
In a recent Life Science Leader podcast, Dr. Jim Doherty, Ph.D., from Acumen Pharmaceuticals, discusses challenges in Alzheimer's treatment, the role of biomarkers, and the latest advancements in CNS drug development. Listen here:
lifescienceleader.com
The Business of Biotech welcomes Dr. Jim Doherty of Acumen Pharmaceuticals to discuss the challenges and advances in Alzheimers treatment, including controversies around amyloid-targeting drugs and...
0
1
1
The 2025 EY Firepower Report highlights key trends in life sciences dealmaking: while volume remains stable, deal value has decreased. As the industry looks to 2025, companies are shifting focus to smaller, strategic deals. Read the full analysis here:
0
0
0
In January, the biotech sector saw continued momentum in funding, with oncology, obesity, and neurological conditions attracting the most private funding. Oncology remained the leader, with nine funding rounds totalling $507 million. Learn more here:
labiotech.eu
The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January 2025.
0
0
0
In 2024, we saw a wave of groundbreaking biosimilar approvals across various therapeutic areas, such as oncology and rheumatology. These approvals may signal a promising future for greater accessibility and affordability in healthcare. Learn more here:
centerforbiosimilars.com
In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options...
0
0
0
Is biotech mergers and acquisitions (M&A) poised for a surge in 2025? 📈 After a slowdown in 2024, where biotech M&A activity dropped significantly, experts are now anticipating a rebound in 2025. Learn more here:
labiotech.eu
There is big hope for biotech M&A in 2025, with a resounding sense that activity will rise again as several important factors come into play.
0
0
0
Scrip’s latest survey signals a positive outlook for biopharma in 2025, with a focus on transformative therapies & partnerships. As macro conditions stabilise, high-quality companies will attract investment, driving innovation and early-stage development.
insights.citeline.com
More than 30 biopharma executives, investors and industry experts shared their views on the environment for funding and deal-making in the year to come. With a patent cliff looming over big pharma at...
0
0
0
Why is 3.5% the magic number for biotech funding? The biotech sector has faced turbulence in recent years due to rising rates and market uncertainty. Experts say once interest rates hit 3.5%, capital costs drop, sparking investor interest and reviving IPOs.
0
1
1
Happy New Year from The RSA Group! We wish you happiness, health and success in 2025 🎆✨
0
1
1
Merry Christmas from The RSA Group! As we wrap up 2024, we want to express our sincere thanks to our employees, clients, and partners for your continued support. Wishing you all a joyful and peaceful holiday season 🎄⭐
0
0
0
As leaders, the energy we bring shapes our teams and culture. Positive energy fosters trust & innovation, while negative energy drains productivity. Protect your energy to lead effectively. Learn more here on Forbes:
0
0
0
As the push for net-zero grows, pharma is embracing decarbonisation. Future State Planning helps assess emissions and create a roadmap, unlocking innovation, cost savings, and a competitive edge in a climate-conscious market. Learn more here:
magazine.pharmatimes.com
The Christmas edition arrives but once a year and, as the cover boldly suggests, this is the Christmas edition! Within the pages of our frost encrusted periodical, we will find 12 industry luminaries...
0
0
1
What were the biggest private biotech investments globally in November 2024? Oncology, central nervous system and genetic disorder players attracted the biggest funding rounds overall. The top three players were Metsera, Alentis Therapeutics and Adcendo.
labiotech.eu
The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024.
0
0
0
In an article on Life Science Leader, Blandine Lacroix, Senior Vice President of Strategy and Rare Disease at Novo Nordisk, reflects on the personal decisions that have shaped her leadership values. Read more here:
lifescienceleader.com
Novo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal needs, and the personal needs of others, in navigating a professional career.
0
0
0
Researchers say they have found the first new treatment for asthma attacks in 50 years. The injection of benralizumab targets a type of white blood cell (called an eosinophil) that can cause inflammation and damage in the lungs. Learn more here:
bbc.co.uk
Around two million asthma and COPD attacks each year could be treated with the drug, a study suggests.
0
0
0
In a guest column on Life Science Leader, Frank D. Lee, CEO of Pacira BioSciences, shares his three core tenets for life science leaders: 1. Practice high-integrity science. 2. Take care of your people. 3. Redefine what patient-first means. Learn more:
lifescienceleader.com
Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.
0
0
0